Cargando…

Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?

BACKGROUND: It has been shown that bcl2, bcl-XL and mcl-1 protein levels are high in chronic lymphocytic leukemia cells, and resultantly, apoptosis does not occur chronic lymphocytic leukemia cells. Apelin and apela (ELABELA/ELA/Toddler) are two peptide ligands for a class A G-protein coupled recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Acik, Didar Yanardag, Bankir, Mehmet, Baylan, Filiz Alkan, Aygun, Bilal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849261/
https://www.ncbi.nlm.nih.gov/pubmed/31718601
http://dx.doi.org/10.1186/s12885-019-6325-6
_version_ 1783469172899971072
author Acik, Didar Yanardag
Bankir, Mehmet
Baylan, Filiz Alkan
Aygun, Bilal
author_facet Acik, Didar Yanardag
Bankir, Mehmet
Baylan, Filiz Alkan
Aygun, Bilal
author_sort Acik, Didar Yanardag
collection PubMed
description BACKGROUND: It has been shown that bcl2, bcl-XL and mcl-1 protein levels are high in chronic lymphocytic leukemia cells, and resultantly, apoptosis does not occur chronic lymphocytic leukemia cells. Apelin and apela (ELABELA/ELA/Toddler) are two peptide ligands for a class A G-protein coupled receptor called apelin receptor. Studies have shown that ELA inhibits apoptosis by inhibiting apoptotic proteins and activating anti-apoptotic proteins. Proteins and genes involved in apoptosis are valuable for targeted cancer therapy. We hypothesized that serum levels may be increased in patients with chronic lymphocytic leukemia based on the antiapoptotic effect of ELA. We compared serum ELABELA levels of healthy volunteers and patients with chronic lymphocytic leukemia. We aimed to draw attention to a new molecule worthy of research in targeted cancer treatment. METHODS: Forty two untreated CLL patients and 41 healthy volunteers were included in the study. Serum ELA levels were measured by using enzyme-linked immunosorbent assay kits (Dhanghai Sunred Biological Technology co. Ltd), automated ELISA reader (Thermo Scientific, FİNLAND) and computer program (Scanlt for Multiscan F.C.2.5.1) in accordance with the manufacturer’s instructions. Statistical analysis was done by Statistical Package for Social Sciences for Windows 20 (IBM SPSS Inc., Chicago, IL) ve MedCalc programs. ELA and variables related to CLL were correlated with Spearman correlation anlysis test. ROC analysis and Youden index method were used to determine a cut off point for ELA. All p-values were 2-sided with statistical significance at 0.05 alpha levels. RESULTS: In our study, we found that serum ELA levels were significantly higher in patients with CLL. CONCLUSIONS: This study highlights that ELA targeting may be a potential therapeutic option for treating CLL.
format Online
Article
Text
id pubmed-6849261
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68492612019-11-15 Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia? Acik, Didar Yanardag Bankir, Mehmet Baylan, Filiz Alkan Aygun, Bilal BMC Cancer Research Article BACKGROUND: It has been shown that bcl2, bcl-XL and mcl-1 protein levels are high in chronic lymphocytic leukemia cells, and resultantly, apoptosis does not occur chronic lymphocytic leukemia cells. Apelin and apela (ELABELA/ELA/Toddler) are two peptide ligands for a class A G-protein coupled receptor called apelin receptor. Studies have shown that ELA inhibits apoptosis by inhibiting apoptotic proteins and activating anti-apoptotic proteins. Proteins and genes involved in apoptosis are valuable for targeted cancer therapy. We hypothesized that serum levels may be increased in patients with chronic lymphocytic leukemia based on the antiapoptotic effect of ELA. We compared serum ELABELA levels of healthy volunteers and patients with chronic lymphocytic leukemia. We aimed to draw attention to a new molecule worthy of research in targeted cancer treatment. METHODS: Forty two untreated CLL patients and 41 healthy volunteers were included in the study. Serum ELA levels were measured by using enzyme-linked immunosorbent assay kits (Dhanghai Sunred Biological Technology co. Ltd), automated ELISA reader (Thermo Scientific, FİNLAND) and computer program (Scanlt for Multiscan F.C.2.5.1) in accordance with the manufacturer’s instructions. Statistical analysis was done by Statistical Package for Social Sciences for Windows 20 (IBM SPSS Inc., Chicago, IL) ve MedCalc programs. ELA and variables related to CLL were correlated with Spearman correlation anlysis test. ROC analysis and Youden index method were used to determine a cut off point for ELA. All p-values were 2-sided with statistical significance at 0.05 alpha levels. RESULTS: In our study, we found that serum ELA levels were significantly higher in patients with CLL. CONCLUSIONS: This study highlights that ELA targeting may be a potential therapeutic option for treating CLL. BioMed Central 2019-11-12 /pmc/articles/PMC6849261/ /pubmed/31718601 http://dx.doi.org/10.1186/s12885-019-6325-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Acik, Didar Yanardag
Bankir, Mehmet
Baylan, Filiz Alkan
Aygun, Bilal
Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
title Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
title_full Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
title_fullStr Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
title_full_unstemmed Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
title_short Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
title_sort can elabela be a novel target in the treatment of chronic lymphocytic leukaemia?
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849261/
https://www.ncbi.nlm.nih.gov/pubmed/31718601
http://dx.doi.org/10.1186/s12885-019-6325-6
work_keys_str_mv AT acikdidaryanardag canelabelabeanoveltargetinthetreatmentofchroniclymphocyticleukaemia
AT bankirmehmet canelabelabeanoveltargetinthetreatmentofchroniclymphocyticleukaemia
AT baylanfilizalkan canelabelabeanoveltargetinthetreatmentofchroniclymphocyticleukaemia
AT aygunbilal canelabelabeanoveltargetinthetreatmentofchroniclymphocyticleukaemia